US “Possibility of landing mutations in America”… Strengthening quarantine for passengers departing from the UK
12-29 06:08
[앵커]
Corona 19 mutant virus originating from the UK is now being confirmed all over the world.
A US health official said it may have landed in the United States as well.
Let’s connect Washington and listen to the Corona 19 situation in the US.
Correspondent Lee Kyung-hee.
[기자]
Yes. Washington.
[앵커]
Starting today, the US has applied stricter quarantine standards for passengers departing from the UK, right?
[기자]
Yes. Starting today, the United States has required all passengers arriving from the UK to submit a negative Corona 19 test received within 72 hours before departure.
This is a measure to block the influx of mutant viruses from the UK.
US health officials, however, have already said the virus may have entered the United States.
In an interview with ABC, the US Assistant Secretary of Health and Welfare Brett Girore said, “Evidence has not yet been found for the presence of the mutant virus, but it is possible given international connectivity.”
He added that there is no evidence that the mutant virus is more serious than the conventional virus.
As to whether the COVID-19 vaccine will be effective against mutations, he said, “There is no complete evidence, but there is good evidence and belief that the vaccine will still be effective.”
In the U.S., a large-scale migration that took place during the Christmas holiday is expected, and if a mutant virus with a greater spreading power spreads, a more serious crisis is a concern.
In the United States, the number of inpatients for Corona 19 has exceeded 100,000 for a month, and on Sunday, the last day of the Christmas holiday, it was counted that 1.28 million people traveled by air in Korea, again recording the highest level since the pandemic.
[앵커]
Let’s hear about vaccines.
Novavex, the US pharmaceutical company, is entering the phase 3 clinical trial of a vaccine for the fifth time in the United States?
[기자]
Yes. Novavex is also of interest in Korea as it is also a pharmaceutical company that the Korean government is negotiating with to purchase vaccines.
NovaVax, a US pharmaceutical company, has announced that it will start phase 3 clinical trials of the COVID-19 vaccine in the United States and Mexico.
Pharmaceutical companies entering the third phase in the United States are the fifth after Pfizer, Modena, AstraZeneca, and Johnson & Johnson.
The third phase of NovaVax is scheduled to be tested in areas with a high rate of COVID-19, targeting 30,000 people over the age of 18.
NovaVax has already entered phase 3 trials in the UK and the results are expected to come out in the first quarter of next year.
Initially, in the US, it was scheduled to enter phase 3 in mid-October, but it was postponed twice due to the problem of expanding the vaccine manufacturing process.
NovaVax has agreed to provide 100 million doses in the US and 60 million doses in the UK.
Until now, in the United States, two vaccines made by Pfizer-Bioentech and Modena have been approved for urgent use and vaccination is being performed. Expect results to come out.
So far, I’ve been telling you from Washington.
Yonhap News TV article inquiries and reports: katok/line jebo23
Unauthorized reproduction-redistribution prohibited>
2020/12/29 06:08 sent